Bayer Reports the US FDA’s Approval of Lynkuet (Elinzanetant) to Treat Vasomotor Symptoms

Shots:The US FDA has approved Lynkuet for the treatment of mod. to sev. vasomotor symptoms due to menopause based on P-III (OASIS-1, 2, & 3) trials, with commercial availability expected at the start of Nov 2025; MAA is under the EMA’s review Efficacy was evaluated in OASIS-1 & 2 trials assessing Lynkuet vs PBO…

ByRidhi RastogiOctober 27, 2025

NEWS

Bayer Reports the CHMP’s Positive Opinion of Elinzanetant to Treat Vasomotor Symptoms

Shots:The CHMP has recommended elinzanetant for treating mod. to sev. vasomotor symptoms linked with menopause or caused by AET related to breast cancer based on P-III (OASIS-1, 2, 3 & 4) trialsOASIS-1 & 2 showed reduced mod. to sev. menopausal VMS vs. PBO at wks. 4 & 12, with >80% pts (incl. those…

ByRidhi RastogiSeptember 23, 2025

THOUGHTSPOT

Menopause Care: How Personalized Medicine Helps You Cope Better (But Challenges Remain)

Menopause is a natural part of aging, yet it can feel anything but natural when the symptoms hit hard. From hot flashes to mood swings, the journey through menopause is unique to every woman, leaving many searching for effective relief tailored to their needs. Imagine a world where your treatment is as unique as your…

ByAndrea LaceyMay 23, 2024

Bayer Reports the US FDA’s Approval of Lynkuet (Elinzanetant) to Treat Vasomotor Symptoms

Bayer Reports the CHMP’s Positive Opinion of Elinzanetant to Treat Vasomotor Symptoms

Menopause Care: How Personalized Medicine Helps You Cope Better (But Challenges Remain)

Contact US

OUR INFORMATION

FOLLOW US